Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S048 - Hot Topics

Monday, February 19; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss a variety of dermatologic 'hot topics' as identified by registrants at the annual meeting.
  • Recognize the medical/surgical implications of those entities, including diagnosis and treatment, especially emerging and innovative therapies.
  • Apply evolving evidence-based knowledge to patient care.

Description

The symposium will address those 'hot topics' established by registrant consensus, a true reflection of member concerns and interests. The somewhat unstructured session will be a 'potpourri' of medical/surgical topics, including some with social and economic import. Expert speakers will provide 'state of the art' material, highlighting recent trends and developments and accenting emerging and innovative therapies. Presentations will be derm relevant, clinically germane, and directly applicable to patient care

Disclosures

  • Baldwin, Hilary E., MD: Allergan, Inc. – A(H); Bayer – SP(NC); Dermira – I(Grants/Research Funding); Galderma Laboratories, L.P. – SP(H); Novan – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – SP(H); Valeant Pharmaceuticals International – SP(H);
  • Benedetto, Anthony V., DO: Allergan, Inc. – I(Fees), SH(ST), SP(H); Astellas Pharma US, Inc – SH(ST); BioDelivery Systems, Inc. – SH(SO); Bristol-Myers Squibb – SH(ST); Brothers Healthcare – B(NC); Castle Biosciences, Inc – A(H); DUSA Pharmaceuticals, Inc. – SP(H); Elan – SH(ST); Excaliard Pharmaceuticals, Inc. – C(H); Johnson & Johnson Consumer Products Company – C(H); Liposonix – SP(H); Lumenis – SP(H); Merz Pharmaceuticals, LLC – C(H), SP(H); Osyris Medical USA – SP(H); sanofi-aventis – SH(ST); Shire – C(H); Stratapharma – C(H), I(H), SP(H);
  • Bergfeld, Wilma Fowler, MD: Aclaris Therapeutics Inc. – I(NC); Concert Pharmaceuticals – I(NC); Eli Lilly and Company – C(NC); Incyte Corporation – I(NC); Johnson and Johnson Consumer Products Company – A(H); Kythera – A(H), I(NC); Pfizer Inc. – A(NC); Procter & Gamble Company – A(H); Samumed, LLC – A(H), I(NC);
  • Draelos, Zoe Diana, MD: Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAÑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding);
  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Halpern, Allan C., MD: Caliber Imaging and Diagnostics Inc. – A(OB); Canfield Scientific, Inc. – C(OB); SciBASE – C(OB);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Monday, February 19
9:00 AM
Dr. Tomecki / Welcome and Introduction
9:05 AM
Dr. Draelos / Cosmeceuticals: Naturally Absurd
9:30 AM
Dr. Baldwin / Acne: What’s New
9:55 AM
Dr. Bergfeld / Hairy Matters: What’s New in Alopecia
10:20 AM
Dr. Eichenfield / Atopic Dermatitis: New Developments
10:45 AM
Dr. Lebwohl / Biologics and Psoriasis: the Beat Goes On
11:10 AM
Dr. Halpern / Melanoma Update 2018
11:35 AM
Dr. Benedetto / What’s New in Cosmetic Surgery
Event Details
  • Date
    Monday, February 19
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 6D
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Kenneth J. Tomecki, MD, FAAD
Speakers
  • Allan C. Halpern, MD, FAAD
  • Anthony V. Benedetto, DO, FAAD
  • Hilary E. Baldwin, MD, FAAD
  • Lawrence F. Eichenfield, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Wilma Fowler Bergfeld, MD, FAAD
  • Zoe Diana Draelos, MD, FAAD - Handout